Therapeutic indications: Atomoxetine is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children of 6 years and older, in adolescents and in adults as part of a comprehensive treatment programme. Treatment must be initiated by a specialist in the treatment of ADHD, such as a paediatrician, child/adolescent psychiatrist, or psychiatrist. Diagnosis should be made according to current DSM criteria or the guidelines in ICD.
Click here for complete product code information.
ADVERSE EVENTS SHOULD BE REPORTED
Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to Neuraxpharm UK Ltd by:
- Email: pv-uk@neuraxpharm.com
- Phone number: +44 330 128 0919
